Mark Jones, MD

Trials

Studies that name Mark Jones, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:02 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT03374488 · Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

  Incyte Corporation · completed · UC (Urothelial Cancer) · study director
• Ph3
  NCT03361865 · Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

  Incyte Corporation · completed · UC (Urothelial Cancer) · study director
• Ph3
  NCT03358472 · Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

  Incyte Corporation · completed · Head and Neck Cancer · study director
• Ph3
  NCT03260894 · Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  Incyte Corporation · completed · Renal Cell Carcinoma (RCC) · study director
• Ph3
  NCT02752074 · A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

  Incyte Corporation · completed · Melanoma · study director
• Ph1/Ph2
  NCT02178722 · Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

  Incyte Corporation · completed · Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer · study director
• Ph1
  NCT01317875 · Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

  Incyte Corporation · completed · Myelofibrosis · study director
• Ph3
  NCT01243944 · Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

  Incyte Corporation · completed · Polycythemia Vera · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 00:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.